Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 1
2019 4
2020 11
2021 4
2022 5
2023 12
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean fengxian zhao (1 results)?
Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
Zhao J, Xu N, Zhu S, Nie L, Zhang M, Zheng L, Cai D, Sun X, Chen J, Dai J, Ni Y, Wang Z, Zhang X, Liang J, Chen Y, Hu X, Pan X, Yin X, Liu H, Zhao F, Zhang B, Chen H, Miao J, Qin C, Zhao X, Yao J, Liu Z, Liao B, Wei Q, Li X, Liu J, Gao AC, Huang H, Shen P, Chen N, Zeng H, Sun G. Zhao J, et al. Among authors: zhao f. Cancer Res. 2024 Jan 2;84(1):154-167. doi: 10.1158/0008-5472.CAN-23-1176. Cancer Res. 2024. PMID: 37847513
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S, Zhao J, Nie L, Yin W, Zhang Y, Zhao F, Ni Y, Zhang X, Wang Z, Dai J, Liu Z, Chen J, Zeng Y, Wang Z, Sun G, Liang J, Zhao X, Zhu X, Tao R, Yang J, He B, Chen N, Shen P, Zeng H. Zhu S, et al. Among authors: zhao f. BMC Med. 2022 Jul 22;20(1):237. doi: 10.1186/s12916-022-02430-0. BMC Med. 2022. PMID: 35864546 Free PMC article.
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Xu N, Zhao J, Zhao F, Liu H, Yin W, Zhu S, Nie L, Sun G, Zheng L, Liu Z, Cai D, Chen J, Dai J, Ni Y, Wang Z, Zhang X, Liang J, Chen Y, Hu X, Pan X, Yin X, Zhu X, Zhang Y, Wang Z, Zeng Y, Wang M, Shen P, Chen N, Zeng H. Xu N, et al. Among authors: zhao f. J Cancer Res Clin Oncol. 2023 Aug;149(10):7247-7258. doi: 10.1007/s00432-023-04639-9. Epub 2023 Mar 13. J Cancer Res Clin Oncol. 2023. PMID: 36907910
The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z, Liu H, Zhao J, Chen J, Zhu S, Dai J, Ni Y, Xu N, Zhao F, He B, Zhang X, Liang J, Sun G, Liu Z, Shen P, Zeng H. Wang Z, et al. Among authors: zhao f. Ann Transl Med. 2023 Mar 15;11(5):201. doi: 10.21037/atm-22-4318. Epub 2023 Mar 9. Ann Transl Med. 2023. PMID: 37007568 Free PMC article. Retracted.
41 results